Expressions of E-Cadherin and Exon V6-Containing Isoforms of CD44 and their Prognostic Values in Human Transitional Cell Carcinoma

Ruey Long Hong, Yeong Shiau Pu, Teh Sheng Hsieh, Jan Show Chu, Wei Jei Lee

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Cell surface adhesion molecules, E-cadherin and exon v6 containing CD44 isoforms (CD44v6), were readily found in well-to-moderately differentiated urothelial cell lines but were down-regulated in poorly differentiated cell lines. One hundred and fifteen tumors of transitional cell carcinoma (TCC) were examined with E-cadheria and CD44v6 specific antibodies. Sixty-five (56.5 percent) tumors exhibited a preserved type while 50 (43.5 percent) showed a reduced type for CD44v6. Sixty-seven (58.3 percent) tumors were classified as the preserved type, and 48 (41.7 percent) were classified as the reduced type for E-cadherin. The staining pattern of E-cadherin was the same as that of CD44v6 in 87.0 percent (100 of 115) of tumors. The frequency of the reduced type was higher in poorly differentiated carcinomas (32 of 52 for CD44v6, p = 0.001; 27 of 52 for E-cadherin, p = 0.112) and tumors with an invasive growth pattern (22 of 27 for CD44v6, p less than 0.001; 20 of 27 for E-cadherin, p less than 0.001) than it was in well-differentiated carcinomas and tumors with expansile growth. However, the association with lymph node involvement or distant metastasis did not reach statistical significance. There was no difference in survival in reference to the expression patterns of CD44v6 and E-cadherin. Furthermore, neither marker was a significant prognostic factor for tumor recurrence and survival according to Cox's multiple variant regression analysis.

Original languageEnglish
Pages (from-to)2025-2028
Number of pages4
JournalJournal of Urology
Volume153
Issue number6
DOIs
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Transitional Cell Carcinoma
Cadherins
Exons
Protein Isoforms
Neoplasms
Carcinoma
Cell Line
Survival
Cell Adhesion Molecules
Growth
Lymph Nodes
Regression Analysis
Staining and Labeling
Neoplasm Metastasis
Recurrence
Antibodies

ASJC Scopus subject areas

  • Urology

Cite this

Expressions of E-Cadherin and Exon V6-Containing Isoforms of CD44 and their Prognostic Values in Human Transitional Cell Carcinoma. / Hong, Ruey Long; Pu, Yeong Shiau; Hsieh, Teh Sheng; Chu, Jan Show; Lee, Wei Jei.

In: Journal of Urology, Vol. 153, No. 6, 1995, p. 2025-2028.

Research output: Contribution to journalArticle

Hong, Ruey Long ; Pu, Yeong Shiau ; Hsieh, Teh Sheng ; Chu, Jan Show ; Lee, Wei Jei. / Expressions of E-Cadherin and Exon V6-Containing Isoforms of CD44 and their Prognostic Values in Human Transitional Cell Carcinoma. In: Journal of Urology. 1995 ; Vol. 153, No. 6. pp. 2025-2028.
@article{17f4eb72b573493596f2cac60dac6918,
title = "Expressions of E-Cadherin and Exon V6-Containing Isoforms of CD44 and their Prognostic Values in Human Transitional Cell Carcinoma",
abstract = "Cell surface adhesion molecules, E-cadherin and exon v6 containing CD44 isoforms (CD44v6), were readily found in well-to-moderately differentiated urothelial cell lines but were down-regulated in poorly differentiated cell lines. One hundred and fifteen tumors of transitional cell carcinoma (TCC) were examined with E-cadheria and CD44v6 specific antibodies. Sixty-five (56.5 percent) tumors exhibited a preserved type while 50 (43.5 percent) showed a reduced type for CD44v6. Sixty-seven (58.3 percent) tumors were classified as the preserved type, and 48 (41.7 percent) were classified as the reduced type for E-cadherin. The staining pattern of E-cadherin was the same as that of CD44v6 in 87.0 percent (100 of 115) of tumors. The frequency of the reduced type was higher in poorly differentiated carcinomas (32 of 52 for CD44v6, p = 0.001; 27 of 52 for E-cadherin, p = 0.112) and tumors with an invasive growth pattern (22 of 27 for CD44v6, p less than 0.001; 20 of 27 for E-cadherin, p less than 0.001) than it was in well-differentiated carcinomas and tumors with expansile growth. However, the association with lymph node involvement or distant metastasis did not reach statistical significance. There was no difference in survival in reference to the expression patterns of CD44v6 and E-cadherin. Furthermore, neither marker was a significant prognostic factor for tumor recurrence and survival according to Cox's multiple variant regression analysis.",
author = "Hong, {Ruey Long} and Pu, {Yeong Shiau} and Hsieh, {Teh Sheng} and Chu, {Jan Show} and Lee, {Wei Jei}",
year = "1995",
doi = "10.1016/S0022-5347(01)67395-6",
language = "English",
volume = "153",
pages = "2025--2028",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Expressions of E-Cadherin and Exon V6-Containing Isoforms of CD44 and their Prognostic Values in Human Transitional Cell Carcinoma

AU - Hong, Ruey Long

AU - Pu, Yeong Shiau

AU - Hsieh, Teh Sheng

AU - Chu, Jan Show

AU - Lee, Wei Jei

PY - 1995

Y1 - 1995

N2 - Cell surface adhesion molecules, E-cadherin and exon v6 containing CD44 isoforms (CD44v6), were readily found in well-to-moderately differentiated urothelial cell lines but were down-regulated in poorly differentiated cell lines. One hundred and fifteen tumors of transitional cell carcinoma (TCC) were examined with E-cadheria and CD44v6 specific antibodies. Sixty-five (56.5 percent) tumors exhibited a preserved type while 50 (43.5 percent) showed a reduced type for CD44v6. Sixty-seven (58.3 percent) tumors were classified as the preserved type, and 48 (41.7 percent) were classified as the reduced type for E-cadherin. The staining pattern of E-cadherin was the same as that of CD44v6 in 87.0 percent (100 of 115) of tumors. The frequency of the reduced type was higher in poorly differentiated carcinomas (32 of 52 for CD44v6, p = 0.001; 27 of 52 for E-cadherin, p = 0.112) and tumors with an invasive growth pattern (22 of 27 for CD44v6, p less than 0.001; 20 of 27 for E-cadherin, p less than 0.001) than it was in well-differentiated carcinomas and tumors with expansile growth. However, the association with lymph node involvement or distant metastasis did not reach statistical significance. There was no difference in survival in reference to the expression patterns of CD44v6 and E-cadherin. Furthermore, neither marker was a significant prognostic factor for tumor recurrence and survival according to Cox's multiple variant regression analysis.

AB - Cell surface adhesion molecules, E-cadherin and exon v6 containing CD44 isoforms (CD44v6), were readily found in well-to-moderately differentiated urothelial cell lines but were down-regulated in poorly differentiated cell lines. One hundred and fifteen tumors of transitional cell carcinoma (TCC) were examined with E-cadheria and CD44v6 specific antibodies. Sixty-five (56.5 percent) tumors exhibited a preserved type while 50 (43.5 percent) showed a reduced type for CD44v6. Sixty-seven (58.3 percent) tumors were classified as the preserved type, and 48 (41.7 percent) were classified as the reduced type for E-cadherin. The staining pattern of E-cadherin was the same as that of CD44v6 in 87.0 percent (100 of 115) of tumors. The frequency of the reduced type was higher in poorly differentiated carcinomas (32 of 52 for CD44v6, p = 0.001; 27 of 52 for E-cadherin, p = 0.112) and tumors with an invasive growth pattern (22 of 27 for CD44v6, p less than 0.001; 20 of 27 for E-cadherin, p less than 0.001) than it was in well-differentiated carcinomas and tumors with expansile growth. However, the association with lymph node involvement or distant metastasis did not reach statistical significance. There was no difference in survival in reference to the expression patterns of CD44v6 and E-cadherin. Furthermore, neither marker was a significant prognostic factor for tumor recurrence and survival according to Cox's multiple variant regression analysis.

UR - http://www.scopus.com/inward/record.url?scp=0029007058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029007058&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)67395-6

DO - 10.1016/S0022-5347(01)67395-6

M3 - Article

C2 - 7538603

AN - SCOPUS:0029007058

VL - 153

SP - 2025

EP - 2028

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -